13D Filing: Longitude Capital Partners, Llc and Corcept Therapeutics Inc (NASDAQ:CORT)

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 7)*

CORCEPT THERAPEUTICS INCORPORATED

(Name of Issuer)

COMMON
STOCK, PAR VALUE $0.001 PER SHARE

(Title of Class of Securities)

218352102

(CUSIP Number)

Patrick G. Enright

Managing Member

Longitude Capital Partners, LLC

800 El Camino Real, Suite 220

Menlo Park, CA 94025

(650) 854-5700

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

March 17, 2017

(Date of Event Which Requires Filing of
this Statement)

If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be
sent.

*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

(Continued on following pages)

(Page 1 of 10 Pages)

¹ Investment funds from limited
partners were used to acquire the securities over which the Reporting Persons have shared voting and dispositive power.

² Consists of 5,721,372 shares
of Common Stock held of record by LVP and 114,675 shares of Common Stock held of record by LCA.

³ The percentage was calculated based upon 112,942,391
shares of Common Stock outstanding as of February 28, 2017, as reported by the Issuer in its Annual Report on Form 10-K filed
with the Commission on March 6, 2017.

¹ Investment funds from limited
partners were used to acquire the securities over which the Reporting Persons have shared voting and dispositive power.

² Consists of 5,721,372 shares
of Common Stock held of record by LVP and 114,675 shares of Common Stock held of record by LCA.

³ The percentage was calculated based upon 112,942,391
shares of Common Stock outstanding as of February 28, 2017, as reported by the Issuer in its Annual Report on Form 10-K filed
with the Commission on March 6, 2017.

¹ Investment funds from limited
partners were used to acquire the securities over which the Reporting Persons have shared voting and dispositive power.

² Consists of 5,721,372 shares
of Common Stock held of record by LVP and 114,675 shares of Common Stock held of record by LCA.

³ The percentage was calculated based upon 112,942,391
shares of Common Stock outstanding as of February 28, 2017, as reported by the Issuer in its Annual Report on Form 10-K filed
with the Commission on March 6, 2017.

¹ Investment funds from limited
partners were used to acquire the securities over which the Reporting Persons have shared voting and dispositive power.

² Consists of 171,610 shares
of Common Stock held of record by Ms. Bakker.

³ Consists of 5,721,372 shares
of Common Stock held of record by LVP, 114,675 shares of Common Stock held of record by LCA and stock options to purchase up to
307,500 shares of Common Stock granted to Mr. Enright, all of which are currently exercisable or exercisable within 60 days
after March 17, 2017.

⁴ The percentage was calculated
based upon 113,249,891 shares of Common Stock outstanding, calculated as follows: the 112,942,391 shares of Common Stock outstanding
as of February 28, 2017, as reported by the Issuer in its Annual Report on Form 10-K filed with the Commission on March 6,
2017, plus the 307,500 shares of Common Stock subject to stock options granted to Mr. Enright that are exercisable as of or
within 60 days after March 17, 2017.

¹ Investment funds from limited
partners were used to acquire the securities over which the Reporting Persons have shared voting and dispositive power.

² Consists of 272,281 shares
of Common Stock held of record by Mr. Enright.

³ Consists of 5,721,372 shares
of Common Stock held of record by LVP, 114,675 shares of Common Stock held of record by LCA and stock options to purchase up to
307,500 shares of Common Stock granted to Mr. Enright, all of which are currently exercisable or exercisable within 60 days
after March 17, 2017.

⁴ The percentage was calculated
based upon 113,249,891 shares of Common Stock outstanding, calculated as follows: the 112,942,391 shares of Common Stock outstanding
as of February 28, 2017, as reported by the Issuer in its Annual Report on Form 10-K filed with the Commission on March 6,
2017, plus the 307,500 shares of Common Stock subject to stock options granted to Mr. Enright that are exercisable as of or
within 60 days after March 17, 2017.

Explanatory Note:

This Amendment No. 7 to Schedule 13D
(the “Amendment”) amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission
(the “Commission”) on April 4, 2008, as amended by Amendment No. 1 filed with the Commission on February 10, 2009,
Amendment No. 2 filed with the Commission on February 11, 2011, Amendment No. 3 filed with the Commission on June 20, 2012, Amendment
No. 4 filed with the Commission on April 1, 2015, Amendment No. 5 filed with the Commission on December 15, 2016 and Amendment
No. 6 filed with the Commission on March 6, 2017 (the “Schedule”). This Amendment is filed on behalf
of Longitude Capital Partners, LLC (“LCP”), Longitude Venture Partners, L.P. (“LVP”), Longitude Capital
Associates, L.P. (“LCA”), Juliet Tammenoms Bakker (“Ms. Bakker”) and Patrick G. Enright (“Mr.
Enright,” and collectively, the “Reporting Persons”), relating to beneficial ownership of the common stock, par
value $0.001 per share (the “Common Stock”), of Corcept Therapeutics Incorporated, a Delaware corporation (the “Issuer”).
The Reporting Persons are filing this Amendment to report changes in their beneficial ownership since the filing of Amendment No. 6
to the Schedule. Except as set forth below, this Amendment does not supplement, restate or amend any of the other information disclosed
in the Schedule as previously filed. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the
Schedule as previously filed.

Item 3 of the Schedule is amended by adding
the following paragraph at the end thereof:

On March 16, 2017, LVP and LCA
engaged in a pro rata distribution of 980,350 and 19,650 shares of common stock of the Issuer, respectively, to their
respective partners for no consideration. LCP, the sole general partner of LVP and LCA, received a pro rata allocation of the
distributed shares in accordance with its ownership percentage in each entity, and on March 16, 2017, further
distributed such allocation to its members on a pro rata basis and for no consideration. Ms. Bakker and
Mr. Enright, managing members of LCP, each received 68,071 shares of common stock of the Issuer in the distribution by
LCP.

Item 4 of the Schedule is amended
by incorporating the information set forth in Item 3 of this Amendment, and adding the following paragraph at the end thereof:

On various dates from March 8 through
March 16, 2017, LVP and LCA sold shares of Common Stock in multiple open market sale transactions and received aggregate gross
cash proceeds of $16,088,680 from all such sales. On March 17, 2017, Ms. Bakker sold shares of Common Stock in one open
market sale transaction and received aggregate gross cash proceeds of $294,681 from such sale. The number of shares sold and the
prices at which such shares were sold are set forth on Schedule A attached hereto, which is incorporated herein by
reference. All such sales were made for general liquidity purposes.

Item 5(a), (b) and (c) of the Schedule
are amended and restated in their entirety to read as follows:

(a) According to the
Annual Report on Form 10-K filed by the Issuer with the Commission on March 6, 2017, as of February 28, 2017, there were
112,942,391 shares of Common Stock outstanding. LVP is the record holder of 5,721,372 shares of Common Stock, representing approximately
5.1% of the issued and outstanding shares of Common Stock. LCA is the record holder of 114,675 shares of Common Stock, representing
approximately 0.1% of the issued and outstanding shares of Common Stock. LVP and LCA may reallocate their holdings of securities
among themselves and may be deemed to beneficially own securities on an aggregated basis. LCP, as general partner of each of LVP
and LCA, has the power to vote and dispose of securities held by each of them. Ms. Bakker and Mr. Enright are the managing
members of LCP and share the decision-making power of LCP with respect to the Issuer’s securities. Ms. Bakker and Mr. Enright
have sole dispositive and voting power over 171,610 and 272,281 shares of Common Stock, respectively, which have been distributed
to them as members of LCP. In addition, Mr. Enright holds stock options to purchase up to 310,000 shares of Common Stock,
of which stock options to purchase up to 307,500 shares of Common Stock are currently exercisable or exercisable within 60 days
after March 17, 2017. Mr. Enright confers with Ms. Bakker prior to making any decisions relating to the voting or
disposition of such stock options or the shares issuable upon exercise of such stock options, and Mr. Enright shares pecuniary
interest in the shares subject to such stock options with the other Reporting Persons pursuant to a contractual relationship.

(b) LVP, LCA and LCP
have shared power to vote and dispose of 5,836,047 shares of Common Stock. Ms. Bakker and Mr. Enright, managing directors
of LCP, may be deemed to have shared voting and dispositive power with respect to all such shares. In addition, Ms. Bakker
and Mr. Enright have shared dispositive and voting power with respect to 307,500 shares of Common Stock subject to stock options
that are currently exercisable or exercisable within 60 days after March 17, 2017, which were issued to Mr. Enright as
consideration for his service as a director on the Board. Ms. Bakker and Mr. Enright have sole dispositive and voting
power over 171,610 and 272,281 shares of Common Stock, respectively, which are held directly by each of them.

(c) Except as reported
in this Amendment, no Reporting Person has effected any transactions in the Issuer’s securities during the period beginning
on February 28, 2017, the day immediately following the date of the last transaction reported in the most recent filing of
an amendment to this Schedule, and ending on March 17, 2017, the date of the last transaction reported in this Amendment.

Item 6 of the Schedule is amended
by incorporating the information set forth in Items 3 and 4 of this Amendment.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 22, 2017

SCHEDULE A

_____________